Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 213-218

  Volm, M ^a   Koomagi R ^a   Mattern, J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Doxorubicin; Immunohistochemistry; Microvessel density; Non small cell lung carcinoma; Resistance; VEGF

Indexed keywords

ANTIBODY; DOXORUBICIN; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL GROWTH FACTORS; FACTOR VIII; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030005057     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. O'Dwyer PJ, Yao KS, Ford P, Godwin AK and Clayton M: Effects of hypoxia on detoxicating enzyme activity and expression in HT 29 colon adenocarcinoma cells. Cancer Res 53: 3082-3087, 1994.
2. Angel P and Karin M: The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991.
3. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Fedes J and Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF Science 246: 1309-1312, 1989.
4. Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
5. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ and Senger DR: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993.
6. World Health Organization: Histological typing of lung tumours. Tumori 6: 253-272, 1981.
7. Carr DT and Mountain CF: Staging lung cancer: In: Lung Cancer. Clinical Diagnosis and Treatment (Straus MJ, ed). New York, Grune and Stratton. 1977, pp 151-161.
8. Volm M, Wayss, K, Kaufmann M and Mattern J: Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15: 983-993, 1979.
9. Volm M, Bruggemann A, Gunther M, Kleine W, Pfleiderer A and Vogt-Schaden M: Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res 45: 5180-5185, 1985.
10. Group for sensitivity testing of tumors (KSST). in vitro short-term test to determine the resistance of human tumors to chemotherapy. Cancer 48: 2127-2135, 1981.
11. Volm M, Drings P, Mattern J, Sonka J, Vogt-Moykopf I and Wayss K: Prognostic significance of DNA patterns and resistance-predictive test in non-small cell lung carcinoma. Cancer 56: 396-403, 1985.
12. Volm M, Bak M, Efferth T, Lathan B and Mattern J: Immuncytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumours and human tumour xenografts by Mab 265/F4. Anticancer Res 8: 531-536, 1988.
13. Volm M, Mattern J and Samsel B: Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase in human lung tumors. Cancer 70: 764-769, 1992.
14. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
15. Ferrara N, Houck K, Jakeman L and Lenng DW: Molecular and biological properties of the vascular endothelial-growth-factor family of proteins. Endocrine Rev 13: 8-32, 1992
16. Macchiarini P, Fontanini G, Hardin MJ, Squartini F and Angeletti CA: Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 340: 145-146, 1992.
17. Yamazaki K, Abe S, Takekawa H, Sukoh H, Watanabe N, Ogura S, Nakajima I, Isobe H, Inoue K and Kawakarni Y: Tumor angiogenesis in human lung adenocarcinoma. Cancer 74: 2245-2250, 1994.
18. Mattern J and Volm M: Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treat Rev 9: 267-298, 1982.
19. Luk CK, Veinot-Drebot L, Tjan E and Tannock IF: Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst 82: 684-692, 1990.
20. Sanna K and Rofstad EK: Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 58: 258-262, 1994.
21. Kalra R, Jones AM, Kirk J, Adams GE and Stratford IJ: The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast cancer cells in vitro. Int J Cancer 54: 650-655, 1993.
22. Rice GC, Ling V and Schimke RT: Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA 84: 9261-9264, 1987.
23. Murphy BJ, Laderoute KR, Chin RJ and Sutherland RM: Metallothionein IIA is up-regulated by hypoxia in human A 431 squamous carcinoma cells. Cancer Res 54: 5808-5810, 1994.
24. Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845 1992.
25. Kim KJ, Li B, Winer J, Armanini M, Gillelt N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
26. Mattern J, Koomagi R, Volm M: Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas Int J Oncol 6: 1059-1062, 1995
27. Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev 13: 139-168, 1994.